JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on July 20, 2007
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
282/29/20991    most recent
M610721200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wayne, G. J
Right arrow Articles by Murphy, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wayne, G. J
Right arrow Articles by Murphy, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Papers In Press, published online ahead of print April 30, 2007
J. Biol. Chem, 10.1074/jbc.M610721200
Submitted on November 20, 2006
Accepted on April 30, 2007

TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is regulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4

Gareth J Wayne, Su-Jun Deng, Augustin Amour, Satty Borman, Rosalie Matico, H Luke Carter, and Gillian Murphy

Department of Oncology, University of Cambridge, Cambridge, Cambridgeshire CB2 0RE

Corresponding Author: gm290{at}cam.ac.uk

ADAMTS-4, aggrecanase-1, is a glutamyl endopeptidase capable of generating catabolic fragments of aggrecan analogous to those released from articular cartilage during degenerative joint diseases such as osteoarthritis. Efficient aggrecanase activity requires the presence of sulfated glycosaminoglycans (GAGs) attached to the aggrecan core protein, implying the contribution of substrate recognition /binding site(s) to ADAMTS-4 activity. In the present study, we demonstrate that inhibition of full-length ADAMTS-4 by full length TIMP-3 (a physiological inhibitor of metalloproteinases) is enhanced in the presence of aggrecan. Furthermore, we show that this modulatory effect on ADAMTS-4 inhibition is both specific to TIMP inhibitors and selective between TIMPs. Our data indicate that this interaction is mediated through the binding of glycosaminoglycans (specifically chondroitin-6-sulfate) of aggrecan to binding sites within the thrombospondin type-1 motif and spacer domains of ADAMTS-4 to form a complex with an improved binding affinity for TIMP-3 over free ADAMTS-4. The results of this study therefore indicate that the cartilage environment can modulate the function of enzyme-inhibitor systems and could have relevance for therapeutic approaches to aggrecanase modulation.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.